1The Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, 1 University Plaza, Brooklyn, New York 11201, USA
2Department of Chemistry Pittsburg State University, 1701 S Broadway, Pittsburg, KS 66762, USA
Establishing reliable and discriminative dissolution methods is critical for maintaining the quality and batch consistency of poorly soluble drug formulations—a process often hindered by conventional development techniques. This review emphasizes the transformative benefits of implementing structured Quality by Design (QbD) and Analytical QbD (aQbD) methodologies. By employing Design of Experiments (DoE), a Method Operable Design Region (MODR) can be optimized to guarantee method robustness. Additionally, implementing systematic evaluation protocols—such as defining a Method Discriminative Design Region (MDDR)—ensures the method’s ability to detect critical variations in formulation and manufacturing processes. Adopting these advanced, science- and risk-based strategies provides a streamlined and dependable framework for creating fit-for-purpose dissolution techniques. Such an approach not only deepens process understanding but also ensures sustained product quality for complex, poorly soluble drugs across their entire lifecycle.
Pharmaceutical Development from Discovery to Patient: The Critical Role of Dissolution Testing
The path from drug discovery to patient delivery requires exhaustive evaluation of safety, efficacy, and quality. For solid oral dosage forms, dissolution testing serves as a fundamental analytical tool, offering crucial data on drug release kinetics that frequently correlate with bioavailability. This becomes particularly complex for poorly soluble compounds, where dissolution rate often determines absorption efficiency. Developing methods that are both robust and capable of detecting product variations is essential for ensuring consistent therapeutic performance. Conventional approaches frequently struggle with these challenges, driving adoption of systematic methodologies like Quality by Design (QbD) and Analytical QbD (aQbD). This review examines how Design of Experiments (DoE) and Method Operable Design Region (MODR) concepts enable development of optimal dissolution methods for insoluble drugs. 1–3
The Multifaceted Importance of Dissolution Testing
As a vital in vitro analytical technique, dissolution testing plays multiple roles in pharmaceutical development:
Obstacles in Developing Poorly Soluble Drugs (BCS II/IV Compounds)
The growing prevalence of poorly water-soluble new chemical entities presents significant formulation challenges:
BCS Classification Challenges:
These compounds frequently encounter:
Designing Discriminative Dissolution Methods
An effective discriminative method must detect variations in Critical Quality Attributes (CQAs) including:
The objective is to create a sensitive quality control tool that identifies clinically relevant batch differences through statistically significant dissolution profile variations.
QbD and aQbD: Modern Analytical Development Frameworks
The QbD approach (ICH Q8) represents a science-based, proactive development strategy focusing on:
aQbD applies these principles specifically to analytical methods, replacing traditional OFAT approaches with:
This paradigm shift enables development of dissolution methods with built-in quality, reliability, and discriminatory power for challenging drug formulations. 5–8
Table 1 Comparative Analysis of Traditional vs. QbD-Based Method Development Approaches
|
Development Aspect |
Conventional (OFAT) Methodology |
QbD/aQbD Framework |
|
Primary Objective |
Verification through final product testing |
Proactive quality integration |
|
Development Strategy |
Sequential parameter optimization |
Multivariate experimentation (DoE-driven) |
|
Process Knowledge |
Limited characterization of factor interplay |
Comprehensive parameter interaction mapping |
|
Operational Control |
Rigidly fixed method parameters |
Flexible MODR-based operation |
|
Method Performance |
Potential robustness issues |
Reliable, optimized analytical operations |
|
Lifecycle Management |
Periodic revalidation |
Continuous performance monitoring |
|
Regulatory Perception |
Standard compliance expectation |
Preferred approach allowing operational flexibility |
Applying aQbD to dissolution method development aims to create methods that are not only fit for purpose but also robust and well-understood.9–12
Introduction to Method Operable Design Region (MODR) as a QbD Tool
A core output of applying DoE within the aQbD framework is the establishment of a Method Operable Design Region (MODR). The MODR is defined as: "The multidimensional combination and interaction of input variables (e.g., material attributes) and process parameters that have been demonstrated to provide assurance of quality." (Adapted from ICH Q8 definition of Design Space) In the context of analytical methods, the MODR represents the ranges for critical method parameters (e.g., pH, agitation speed, surfactant concentration for dissolution) within which the method has been proven to consistently meet its predefined performance criteria (the ATP). Establishing an MODR offers significant advantages:
The MODR is determined through systematic experimentation (DoE) and statistical modeling, providing a scientifically sound basis for the method's control strategy.
REVIEW SCOPE AND OBJECTIVES
This review aims to provide a comprehensive overview of the strategies and considerations involved in developing and validating discriminative dissolution methods specifically for poorly soluble drugs, leveraging the principles of Analytical Quality by Design (aQbD) and the concept of the Method Operable Design Region (MODR).
The key objectives are:
By synthesizing current knowledge and drawing upon relevant case studies, this review intends to serve as a valuable resource for pharmaceutical scientists involved in formulation development, analytical method development, and quality assurance for poorly soluble drug products.
Fundamentals of Discriminatory Dissolution
Understanding the fundamental principles of discriminatory dissolution testing is essential before delving into advanced method development strategies like QbD and MODR. This section outlines the core purpose, regulatory context, influencing factors, and the often-complex relationship between in vitro findings and in vivo outcomes, particularly for poorly soluble drugs.7,13–17
Purpose: Differentiating Critical Quality Attributes (CQAs)
The primary purpose of a discriminatory dissolution method is not necessarily to perfectly replicate the in vivo gastrointestinal environment, but rather to serve as a sensitive quality control tool capable of differentiating between batches of a drug product based on variations in their Critical Quality Attributes (CQAs)18. These CQAs are physical, chemical, biological, or microbiological attributes or characteristics that should be within an appropriate limit, range, or distribution to ensure the desired product quality. In the context of dissolution, relevant CQAs often include: 19–23
Critical Factors Influencing Dissolution Performance
1. API-Specific Characteristics
2. Formulation Design Elements
3. Manufacturing Process Variables
Regulatory Framework for Discriminatory Methods
Current Regulatory Expectations
Implementation Challenges for Poorly Soluble Compounds
Performance Verification Strategy
Factors Governing Dissolution Performance of Poorly Soluble Drugs
I. Active Pharmaceutical Ingredient (API) Characteristics
II. Formulation Design Factors
A. Excipient Selection Matrix
B. Dosage Form Architecture
III. Manufacturing Process Controls
Critical Interactions for Method Development
Table 2 Factors affecting Dissolution (Poorly Soluble Drugs)
|
Category |
Factor |
Potential Impact on Dissolution (Poorly Soluble Drugs) |
|
API Properties |
Solubility (Intrinsic, pH-dependent) |
Rate-limiting; dictates medium requirements |
|
Particle Size / Surface Area |
Smaller size generally increases rate |
|
|
Solid-State Form (Polymorphism/Amorphous) |
Can significantly alter solubility & rate |
|
|
Wettability |
Poor wetting hinders dissolution |
|
|
Formulation Variables |
Disintegrant Level |
Affects tablet breakup & surface area exposure |
|
Binder Type/Level |
Influences hardness, disintegration |
|
|
Lubricant Level |
Excess hydrophobic lubricant can impede dissolution |
|
|
Surfactants/Solubilizers (in formulation) |
Can enhance local solubility |
|
|
Drug Loading |
May affect release rate at high concentrations |
|
|
Process Parameters |
Compression Force |
Affects hardness, porosity, disintegration |
|
Granulation Method/Parameters |
Influences granule properties, disintegration |
|
|
Coating |
Can delay disintegration/dissolution onset |
Strategic Development of Discriminatory Dissolution Methods: Bridging In Vitro and In Vivo Relevance
1. Critical Considerations for Method Development
To ensure meaningful discriminatory power, dissolution methods must:
2. In Vitro Discrimination vs. In Vivo Performance: Key Insights
While a dissolution method may detect minor batch variations, not all in vitro differences translate to in vivo effects due to:
3. Value of Discriminatory Methods Without IVIVC
Despite potential disconnects, robust dissolution testing provides essential benefits:
Table 3 Application and purpose of discriminatory methods
|
Application |
Purpose |
|
Batch Consistency |
Ensures equivalence between pre- and post-change batches (e.g., SUPAC). |
|
Process Control |
Identifies critical manufacturing parameters (e.g., granulation, compression). |
|
Risk Reduction |
Flags batches with atypical release profiles that may affect bioavailability. |
|
Regulatory Compliance |
Meorts (e.g., ICH Q6A, FDA dissolution guidance). |
4. Pragmatic Approach to Discrimination
A well-designed discriminatory method prioritizes practical quality control over absolute in vivo predictability. By targeting the most critical CQAs, it ensures product consistency while acknowledging the complexities of bioavailability in poorly soluble drugs.
Method Development Approaches: Traditional vs. QbD
Creating dissolution methods - particularly those capable of discriminating between formulations for poorly soluble drugs - demands a methodical development strategy. In the past, these techniques were typically established through experimental, iterative testing methods. Today's pharmaceutical science, however, progressively adopts more rigorous, scientifically-grounded methodologies such as Quality by Design (QbD) principles.
Challenges of One-Factor-at-a-Time (OFAT) Methodology in Dissolution Development
The conventional OFAT approach to analytical method development presents several critical limitations when applied to complex dissolution systems:
These shortcomings make OFAT particularly inadequate for developing dissolution methods targeting poorly soluble compounds where multiple interacting parameters must be optimized.
Analytical Quality by Design (aQbD) Framework for Enhanced Dissolution Development
The aQbD approach provides a structured, science-driven alternative with distinct advantages:
Phase 1: Analytical Target Profile (ATP) Establishment
Phase 2: Comprehensive Risk Assessment
Phase 3: Design of Experiments (DoE) Implementation
This systematic workflow enables development of dissolution methods with built-in quality, particularly valuable for challenging BCS Class II/IV compounds requiring precise discriminatory capability.
Key Advantages of the aQbD Approach:
The transition from empirical OFAT to model-based aQbD represents a paradigm shift in dissolution methodology, particularly critical for poorly soluble drug products where traditional approaches often prove inadequate48–51.
Establishing the Method Operable Design Region (MODR) via DoE
The transition from risk assessment to practical method development occurs through systematic Design of Experiments (DoE) implementation, a cornerstone of the Analytical Quality by Design (aQbD) approach. This process begins with careful selection of Critical Method Parameters (CMPs) - those variables most likely to impact dissolution performance for poorly soluble drugs. Typical CMPs encompass medium composition characteristics (pH, buffer strength, surfactant type and concentration), hydrodynamic conditions (apparatus selection, agitation speed), and operational factors like deaeration methods. These parameters are studied across scientifically justified ranges derived from preliminary experiments and literature data, ensuring exploration of a sufficiently broad operational space. The experimental strategy moves beyond traditional OFAT methodology through structured DoE designs tailored to development objectives. Initial screening designs efficiently identify dominant factors from numerous potential variables, while subsequent optimization designs employ more sophisticated arrangements (full factorial, response surface methodologies) to precisely characterize parameter interactions and nonlinear effects. Modern statistical software facilitates both design generation and subsequent data analysis, with center point replicates providing crucial information about experimental variability and system curvature. During execution, comprehensive dissolution profiles are captured with particular attention to key timepoints and derived metrics that reflect both dissolution rate and completeness. Advanced statistical treatment transforms raw dissolution data into predictive mathematical models through ANOVA and regression techniques. These models quantify how each CMP influences dissolution behavior while revealing important parameter interactions often missed by conventional approaches. The analysis employs multiple diagnostic tools - from Pareto charts identifying dominant effects to multidimensional contour plots visualizing complex relationships. This mathematical foundation enables precise MODR determination by overlaying acceptance criteria from the Analytical Target Profile across all critical responses. The resulting MODR represents a scientifically validated operational space where method performance is guaranteed to meet all quality requirements. Final verification through targeted confirmation experiments provides the essential link between statistical prediction and practical performance. By testing edge-of-design conditions and intermediate points, developers confirm the MODR's real-world reliability before method implementation. This rigorous approach yields dissolution methods with built-in robustness, particularly valuable for poorly soluble drugs where traditional development often struggles to achieve adequate discrimination. The MODR framework additionally provides regulatory flexibility, allowing parameter adjustments within validated ranges without requiring full revalidation - a significant advantage for lifecycle management. Ultimately, this systematic methodology transforms dissolution development from an empirical exercise to a knowledge-driven process grounded in sound scientific principles.
Assessing and Validating Discriminatory Power using QbD
After establishing a robust dissolution method with its Method Operable Design Region (MODR), the critical next step involves validating the method's discriminatory power. This evaluation ensures the method can reliably detect meaningful variations in product characteristics that may affect drug release. The process begins by identifying Critical Formulation and Process Parameters (CFPs/CPPs) known to influence dissolution behavior, such as API particle size, excipient levels, and manufacturing conditions. These parameters are selected based on prior risk assessments and scientific understanding of the formulation. To assess discriminatory capability, two main experimental approaches are employed. The first involves preparing batches with intentional, controlled variations from target specifications, testing both expected manufacturing ranges and extreme cases. A more comprehensive alternative uses Design of Experiments (DoE) to systematically evaluate multiple parameter interactions simultaneously, providing deeper insight into the method's sensitivity. Recent studies have successfully demonstrated this approach by examining concurrent variations in key factors like API particle size and tablet hardness. The evaluation utilizes quantitative comparison tools to objectively measure discrimination. Regulatory-standard metrics include the similarity factor (f2), where values below 50 indicate significant profile differences, and the complementary difference factor (f1). More advanced multivariate analyses, such as Principal Component Analysis and Mahalanobis distance calculations, offer enhanced capability to detect subtle but potentially important variations that conventional metrics might miss. While visual profile comparison provides initial insights, it lacks the objectivity required for formal validation. This systematic approach to discrimination validation ensures the dissolution method meets both scientific and regulatory requirements, combining operational robustness (established through MODR) with appropriate sensitivity to product quality attributes. For poorly soluble drugs where dissolution often dictates bioavailability, such comprehensive validation is particularly crucial, as it helps ensure the method can detect variations that may affect clinical performance while maintaining reliability for quality control purposes throughout the product lifecycle.
Table 4 Common Dissolution Profile Comparison Tools
|
Tool |
Principle |
Interpretation for Discrimination |
Regulatory Acceptance |
Notes |
|
Similarity Factor (f2) |
Logarithmic transformation of the sum of squared errors |
f2 < 50 indicates Dissimilarity (Discrimination) |
High (FDA, EMA) |
Most common; specific calculation rules apply |
|
Difference Factor (f1) |
Average absolute percent difference across time points |
Higher f1 indicates greater difference |
Lower than f2 |
Less sensitive to profile shape |
|
Multivariate Distance |
Statistical distance between profiles in multi-D space |
Larger distance indicates greater difference |
Varies; supportive |
Considers profile shape and variability |
|
Visual Comparison |
Subjective observation of profile plots |
Initial assessment only |
Low (as sole basis) |
Prone to bias |
Validation of Discriminatory Power in QbD-Compliant Dissolution Methods
The selection of appropriate analytical tools for evaluating discriminatory power must consider both scientific objectives and regulatory requirements. A widely accepted benchmark involves demonstrating similarity factor (f2) values below 50 when testing formulations with intentionally introduced, clinically relevant variations. This quantitative approach provides objective evidence of the method's ability to distinguish between products with meaningful differences in critical quality attributes. Building upon the established Method Operable Design Region (MODR) concept, recent advancements in Analytical Quality by Design (aQbD) have introduced the Method Discriminative Design Region (MDDR). This innovative framework, as demonstrated in contemporary research, complements the MODR by delineating the boundaries of formulation and process variability that the dissolution method can reliably detect. While MODR ensures analytical robustness, MDDR specifically characterizes the method's sensitivity to product variations through quantitative metrics such as the f2 value. Advanced visualization techniques, including Formulation-Discrimination Correlation Diagrams, facilitate comprehensive interpretation of MDDR data. These multidimensional plots enable researchers to identify threshold levels for critical parameters, visualize interaction effects between formulation variables, and precisely define the operational space where the method demonstrates appropriate discriminatory power. Such graphical representations prove particularly valuable when assessing complex relationships between multiple formulation attributes and dissolution performance. Concurrent with discrimination studies, thorough method validation remains essential per ICH Q2(R1) guidelines. This comprehensive evaluation encompasses specificity assessments to confirm analytical interference-free measurements, linearity verification across the relevant concentration range, accuracy determination through recovery studies, and precision evaluation at multiple levels (repeatability and intermediate precision). While MODR establishment addresses many robustness concerns, targeted verification studies around optimal operating conditions provide additional assurance of method reliability. Solution stability assessments complete the validation package, ensuring analytical integrity throughout the testing window. The integration of these elements - from MDDR determination to conventional validation parameters - creates a holistic framework for dissolution method development. This approach, as evidenced in recent pharmaceutical research, yields analytical procedures that simultaneously achieve operational robustness through MODR and appropriate sensitivity to product variations through MDDR. For poorly soluble drug products where dissolution often serves as the critical quality indicator, such comprehensive method characterization provides essential assurance of both analytical reliability and clinical relevance throughout the product lifecycle. The resulting dissolution methods fulfill stringent quality control requirements while maintaining the flexibility inherent in modern QbD-based analytical development paradigms. 52–54
Future Perspectives & Recommendations
The field of dissolution testing for poorly soluble drugs is undergoing significant transformation, driven by scientific innovation and evolving regulatory standards. A key focus moving forward is enhancing the physiological relevance of in vitro dissolution data through integration with Physiologically Based Pharmacokinetic (PBPK) modelling and the adoption of advanced biorelevant media and apparatus, such as the USP IV flow-through cell system. These advancements aim to bridge the gap between in vitro dissolution profiles and in vivo performance, ensuring more predictive quality control measures. Technological progress is also reshaping dissolution method development through the incorporation of multivariate data analysis, Process Analytical Technology (PAT), and automated real-time monitoring. These tools facilitate deeper process understanding, improve efficiency, and enable more robust method optimization. Additionally, emerging Analytical Quality by Design (aQbD) concepts, such as the Method Discriminative Design Region (MDDR) and Formulation-Discrimination Correlation Diagrams, are gaining traction for their ability to systematically assess and enhance discriminatory power. These frameworks, combined with lifecycle management strategies, allow for continuous method refinement and regulatory adaptability. To maximize the effectiveness of dissolution testing, early adoption of QbD principles is strongly recommended, ensuring built-in robustness from the outset of method development. A mechanistic understanding of how critical material attributes and process parameters influence dissolution behavior is essential for designing predictive and discriminating methods. Furthermore, the level of discriminatory power should be tailored based on risk assessment, prioritizing clinically relevant variations. Continuous learning and data-driven refinements throughout the product lifecycle will further optimize dissolution methods, ensuring they remain aligned with both scientific advancements and regulatory expectations. By embracing these forward-looking strategies, the pharmaceutical industry can develop dissolution methods that are not only robust and discriminatory but also physiologically relevant, ultimately safeguarding the quality and performance of poorly soluble drug products.
CONCLUSION
The development of robust and discriminatory dissolution methods for poorly soluble drugs represents a critical challenge in pharmaceutical quality control, where conventional approaches often prove inadequate due to inherent formulation complexities. This review demonstrates how the implementation of Quality by Design (QbD) and Analytical QbD (aQbD) principles offers a transformative solution to these challenges. By employing structured methodologies such as Design of Experiments (DoE), researchers can systematically establish a Method Operable Design Region (MODR) that ensures analytical robustness across operational variations. Beyond robustness, the concept of a Method Discriminative Design Region (MDDR) provides a novel framework for validating a method's ability to detect meaningful product variations. This dual approach—combining MODR for method reliability and MDDR for discriminatory sensitivity—represents a paradigm shift in dissolution science. The integration of these science- and risk-based strategies facilitates the development of optimized dissolution methods that are not only technically sound but also clinically relevant. Such modernized approaches offer multiple advantages: enhanced process understanding, greater regulatory flexibility, and improved lifecycle management of dissolution methods. For poorly soluble drugs—where dissolution often serves as the critical quality attribute—these advancements provide a more reliable and efficient pathway to ensure consistent product performance. Ultimately, the adoption of QbD principles in dissolution method development represents a significant step forward in pharmaceutical quality assurance, enabling more predictive and meaningful quality control for challenging drug products.
CONFLICT OF INTEREST
The author declares that there are no conflicts of interest regarding the publication of this article.
REFERENCES
Purva Patel*, Arjun Chaudhari, Akash Patel, Discriminative Dissolution Development and Validation of Poorly Soluble Drugs Using Method Operable Design Region, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 5, 950-965. https://doi.org/10.5281/zenodo.15350900
10.5281/zenodo.15350900
